Depmann Martine, Broer Simone L, van der Schouw Yvonne T, Tehrani Fahimeh R, Eijkemans Marinus J, Mol Ben W, Broekmans Frank J
1Department of Reproductive Medicine and Gynecology, University Medical Center Utrecht, Utrecht, The Netherlands 2Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands 3Reproductive Endocrinology Research Center, Shahid Behesti University of Medical Sciences, Velenjak, Iran 4The Robinson Research Institute, School of Pediatrics and Reproductive Health, University of Adelaide, Adelaide, SA, Australia.
Menopause. 2016 Feb;23(2):224-32. doi: 10.1097/GME.0000000000000509.
This review aimed to appraise data on prediction of age at natural menopause (ANM) based on antimüllerian hormone (AMH), antral follicle count (AFC), and mother's ANM to evaluate clinical usefulness and to identify directions for further research.
We conducted three systematic reviews of the literature to identify studies of menopause prediction based on AMH, AFC, or mother's ANM, corrected for baseline age.
Six studies selected in the search for AMH all consistently demonstrated AMH as being capable of predicting ANM (hazard ratio, 5.6-9.2). The sole study reporting on mother's ANM indicated that AMH was capable of predicting ANM (hazard ratio, 9.1-9.3). Two studies provided analyses of AFC and yielded conflicting results, making this marker less strong.
AMH is currently the most promising marker for ANM prediction. The predictive capacity of mother's ANM demonstrated in a single study makes this marker a promising contributor to AMH for menopause prediction. Models, however, do not predict the extremes of menopause age very well and have wide prediction interval. These markers clearly need improvement before they can be used for individual prediction of menopause in the clinical setting. Moreover, potential limitations for such use include variations in AMH assays used and a lack of correction for factors or diseases affecting AMH levels or ANM. Future studies should include women of a broad age range (irrespective of cycle regularity) and should base predictions on repeated AMH measurements. Furthermore, currently unknown candidate predictors need to be identified.
本综述旨在评估基于抗苗勒管激素(AMH)、窦卵泡计数(AFC)和母亲自然绝经年龄(ANM)预测自然绝经年龄(ANM)的数据,以评估其临床实用性并确定进一步研究的方向。
我们对文献进行了三项系统评价,以确定基于AMH、AFC或母亲的ANM并校正基线年龄的绝经预测研究。
在检索的关于AMH的六项研究中,均一致表明AMH能够预测ANM(风险比为5.6 - 9.2)。唯一一项报告母亲ANM的研究表明,AMH能够预测ANM(风险比为9.1 - 9.3)。两项提供AFC分析的研究得出了相互矛盾的结果,使得该标志物的预测能力较弱。
AMH是目前预测ANM最有前景的标志物。一项研究中显示的母亲ANM的预测能力,使其成为与AMH共同预测绝经的有前景的因素。然而,模型对绝经年龄的极端值预测效果不佳,且预测区间较宽。在临床环境中用于个体绝经预测之前,这些标志物显然需要改进。此外,此类应用的潜在限制包括所使用的AMH检测方法的差异以及缺乏对影响AMH水平或ANM的因素或疾病的校正。未来的研究应纳入更广泛年龄范围的女性(无论月经周期是否规律),并应基于多次AMH测量进行预测。此外,需要识别目前未知的候选预测因子。